{"classes":[{"categories":[{"measurements":[{"comment":"We were unable to assess participant response to treatment due to missingness of data required for determination of response.","groupId":"OG000","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Complete Response (CR), Partial Response (PR), and Minor Response (MR) each required stable bone disease and normal calcium levels. CR also required 100% serum protein electrophoresis (SPEP) reduction, negative immunofixation (IF), 100% urine protein electrophoresis (UPEP)reduction, and \\<5% plasma cells in bone marrow. PR also required \\>=50% SPEP reduction, \\>=90% UPEP reduction, and \\>=50% reduction in plasma cells in bone marrow. MR also required \\>=25% SPEP reduction, \\>=50% UPEP reduction, and \\> 25% reduction in plasma cells.","groups":[{"description":"All subjects received bortezomib 1.3mg/m\\^2 on Days 1, 4, 15, and 18 every 28 days and dexamethasone 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days. Following US FDA approval of doxorubicin HCl liposome injection in combination with bortezomib in May 2007, the study was amended to allow combination treatment with both bortezomib and doxorubicin HCl liposome injection 30 mg/m\\^2 on Day 4 every 28 days with dexamethasone. The target goal was 8 cycles of treatment.","id":"OG000","title":"Treatment Group"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Every 8 weeks from start of treatment until end of treatment","title":"Number of Participants With Treatment Response","type":"SECONDARY","unitOfMeasure":"Participants"}